interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Rezafungin Acetate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Rezafungin Acetate, and who makes it?

Rezafungin Acetate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Rezafungin Acetate1 dosage-form group in the Orange Book
0generic makers listed
  1. Rezafungin Acetate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Powder, Intravenous

Brand listed, no generic listed as marketed

Brand listed as marketed: Rezzayo. No generic is listed as marketed.

2020202520302035204001brand 2023data datePatent 11654196 listed to expire 2 March 2032Patent 10702573 listed to expire 14 March 2033Patent 9526835 listed to expire 14 March 2033Patent 8722619 listed to expire 9 May 2036Patent 11712459 listed to expire 15 March 2037Patent 11819533 listed to expire 11 July 2038Patent 11197909 listed to expire 14 July 2038Exclusivity NCE to 22 March 2028Exclusivity ODE-426 to 22 March 2030Exclusivity GAIN to 22 March 2033Exclusivity GAIN to 22 March 2035
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 22 March 2028Exclusivity NCE Rezzayo
  • 22 March 2030Exclusivity ODE-426 Rezzayo
  • 22 March 2033Exclusivity GAIN Rezzayo
  • 22 March 2035Exclusivity GAIN Rezzayo
  • 2 March 2032Patent 11654196 drug substance
  • 14 March 2033Patent 10702573 drug substance
  • 14 March 2033Patent 9526835 drug substance
  • 9 May 2036Patent 8722619 drug substance
  • 15 March 2037Patent 11712459 drug product
  • 11 July 2038Patent 11819533 drug substance
  • 14 July 2038Patent 11197909 drug substance

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.